Pharma Update

Ocrevus: Continued growth in all markets around the world Opportunity to expand overall CD20 class and gain class share 50% 40% MS total patient share (global)* 30% 20% 10% 0% Q1 Q3 Q1 18 18 19 Q3 Q1 Q3 ⚫Ocrevus Other CD20 Q1 Q3 Q1 Q3 Q1 19 20 20 21 21 22 22 23 ABCREPS mAbs Ocrevus performance update • · · • Roche OCREVUS ocrelizumab IR call on October 30 Ocrevus with 22% patient share globally (>300k pts treated) High proportion of patients free of disease progression after 10 years of treatment highlighting importance of early treatment Higher retention rate than other MS medicines Only drug in RMS and PPMS Outlook • · • Orals • Positive Ph III (OCARINA II) results to be presented at ECTRIMS 10 year safety/efficacy data to be presented at ECTRIMS Treatment of choice for family planning: Pregnancy/lactation data to be submitted to health authorities in 2024 Ph III (GAVOTTE/MUSETTE) Ocrevus high dose: Trials fully recruited; potential to further improve control of disability progression Further potential to grow our MS franchise: fenebrutinib has opportunity to disrupt oral class, currently comprising >40% of the global market *Global patient share includes US, 18, JP; ABCREPS includes interferons and Copaxone, Other mAbs includes Tysabri, Lemtrada, and Zinbryta; Other CD20 includes Kesimpta, Briumvi; MS-multiple sclerosis; SC=subcutaneous 51

View entire presentation